Kluczowe, randomizowane, otwarte badanie Optune® (Tumor Treating Fields) w skojarzeniu z RT i TMZ w leczeniu nowo zdiagnozowanego GBM (EF-32)
EF-32: Kluczowe, randomizowane, otwarte badanie Optune® (pola leczące guza, 200 kHz) w skojarzeniu z radioterapią i temozolomidem w leczeniu nowo zdiagnozowanego glejaka wielopostaciowego
To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
Optune® is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune® has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.
The current standard of care for GBM includes the addition of Optune® to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).
The purpose of the current study is to test if the earlier introduction of Optune®, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.
The study will randomize 950 subjects equally to one of two treatment arms:
- Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune® System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune® treatment.
- Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune®.
All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune® according to the current standard of care regimen.
Optune® will continue until second disease progression per 2010 RANO Criteria unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.
After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.
If the subject is assigned to the treatment group that will start Optune® therapy during radiation therapy, Optune® therapy will begin within 10 days of enrolling in the study and no later than the first day of RT and TMZ treatment.
After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the site and sponsor.
Subjects will be required to return to the clinic per the study protocol.
After the second disease progression, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune® or after second disease progression, the latter of the two per protocol.
After completing active participation in the study, subjects will be contacted once per month to answer basic questions about their health status.
Typ studiów
Typ studiów
Zapisy (Rzeczywisty)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Innsbruck
-
Innsbruck, Innsbruck, Austria, 6020
- Innsbruck University Hospital
-
-
Linz
-
Linz, Linz, Austria, 4020
- Kepler University Hospital
-
-
State of Salzburg
-
Salzburg, State of Salzburg, Austria, 5020
- University Hospital Salzburg
-
-
-
-
-
Liège, Belgia, B35, 4000
- University Hospital Liege - Sart Tilman
-
-
-
-
Brno
-
Brno, Brno, Czechy, 656 53
- Masaryk Memorial Cancer Institute
-
-
Pilsen
-
Pilsen, Pilsen, Czechy, 305 99
- University Hospital Plzeň
-
-
Prague
-
Prague, Prague, Czechy, 150 30
- Na Homolce Hospital
-
-
-
-
-
Angers, Francja, 49055
- Institut de cancérologie de l'Ouest
-
Bron, Francja, 69677
- Pierre Wertheimer Hospital
-
Marseille, Francja, 13305
- Hôpital la Timone
-
Nice, Francja, 06000
- University Hospital Nice
-
Paris, Francja, 75013
- Pitié-Salpêtrière University Hospital
-
Saint-Herblain, Francja, 44800
- Institut de cancérologie de l'Ouest
-
Toulouse, Francja, 31059
- University Institute Cancer Toulouse Oncopole
-
Villejuif, Francja, 94805
- Gustave Roussy Institute
-
-
-
-
-
Jerusalem, Izrael, 9112001
- Hadassah Medical Center - Ein Kerem
-
-
Haifa District
-
Haifa, Haifa District, Izrael, 3109601
- Rambam Medical Center
-
-
Petah Tikva
-
Petah Tikva, Petah Tikva, Izrael, 49100
- Rabin Medical Center
-
-
Ramat Gan
-
Ramat Gan, Ramat Gan, Izrael, 52621
- Sheba Medical Center
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Izrael, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
Hokkaido
-
Sapporo, Hokkaido, Japonia, 060-8648
- Hokkaido University Hospital
-
-
Ishikawa-ken
-
Kanazawa, Ishikawa-ken, Japonia, 920-8641
- Kanazawa University Hospital
-
-
Saitama
-
Hidaka-shi, Saitama, Japonia, 350-1298
- Saitama Medical University International Medical Center
-
-
Tokyo-To
-
Mitaka-shi, Tokyo-To, Japonia, 181-8611
- Kyorin University Hospital
-
Shinjuku-ku, Tokyo-To, Japonia, 162-8666
- Tokyo Women's Medical University Hospital
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V5Z 4E6
- BC Cancer - Vancouver
-
-
Nova Scotia
-
Sydney, Nova Scotia, Kanada, B1P 1P3
- Nova Scotia Health Authority
-
-
Ontario
-
Ottawa, Ontario, Kanada
- The Ottawa Hospital Cancer Centre
-
Toronto, Ontario, Kanada
- Princess Margaret Cancer Centre
-
Toronto, Ontario, Kanada
- Sunnybrook Research Institute - Odette Cancer Centre
-
-
Quebec
-
Montreal, Quebec, Kanada, H2X1R9
- CHUM Centre de Recherche
-
Sherbrooke, Quebec, Kanada
- Universite de Sherbrooke - Sherbrooke Centre Hospitalier Universita
-
-
-
-
-
Essen, Niemcy, 45147
- University Hospital Essen
-
Freiburg im Breisgau, Niemcy, 79106
- University Medical Center Freiburg
-
Leipzig, Niemcy, 04103
- University Hospital Leipzig
-
Munich, Niemcy, 81675
- Rechts der Isar Hospital
-
Tübingen, Niemcy, 72076
- University Hospital Tübingen
-
-
-
-
Alabama
-
Birmingham, Alabama, Stany Zjednoczone, 35243
- Grandview Cancer Center
-
-
Arizona
-
Gilbert, Arizona, Stany Zjednoczone, 85234
- Banner MD Anderson Cancer Center
-
Phoenix, Arizona, Stany Zjednoczone, 85054
- Mayo Clinic- Arizona
-
Tucson, Arizona, Stany Zjednoczone, 85719
- University of Arizona Cancer Center
-
-
Arkansas
-
Fayetteville, Arkansas, Stany Zjednoczone, 72762
- Highlands Oncology Group
-
-
California
-
Burbank, California, Stany Zjednoczone, 91505
- Providence St. Joseph Medical Center and The Roy and Patricia Disney Family Cancer Center
-
Duarte, California, Stany Zjednoczone, 91010
- City of Hope National Medical Center
-
Fullerton, California, Stany Zjednoczone, 92835
- TRIO - St. Jude Heritage Healthcare/St. Jude Medical Center
-
La Jolla, California, Stany Zjednoczone, 92093
- University of California at San Diego - Moores Cancer Center
-
Los Angeles, California, Stany Zjednoczone, 90048
- Cedars - Sinai Medical Center
-
Los Angeles, California, Stany Zjednoczone, 90033
- Norris Comprehensive Cancer Center at USC
-
Newport Beach, California, Stany Zjednoczone, 92663
- Hoag Memorial Hospital - Hoag Cancer Center
-
Orange, California, Stany Zjednoczone, 92868
- St. Joseph Hospital of Orange
-
Orange, California, Stany Zjednoczone, 92868
- University of California - Irvine/UCI Medical Center
-
Palo Alto, California, Stany Zjednoczone, 94303
- Stanford University Cancer Institute
-
San Diego, California, Stany Zjednoczone, 92123
- Sharp Memorial Hospital - X-Ray Medical Group Radiation Oncology
-
San Francisco, California, Stany Zjednoczone, 94143
- University of California San Francisco Medical Center
-
Santa Monica, California, Stany Zjednoczone, 90404
- John Wayne Cancer Institute at St. John's Health Center
-
-
Colorado
-
Aurora, Colorado, Stany Zjednoczone, 80045
- University of Colorado Cancer Center Anschutz
-
Englewood, Colorado, Stany Zjednoczone, 80113
- HCA Research Institute - Blue Sky Neurology - Denver
-
-
Connecticut
-
Hartford, Connecticut, Stany Zjednoczone, 06106
- Hartford Healthcare Medical Group - Hartford Hospital The Gray Cancer Center
-
-
Florida
-
Boca Raton, Florida, Stany Zjednoczone, 33486
- Lynn Cancer Institute, Marcus Neuroscience Institute
-
Jacksonville, Florida, Stany Zjednoczone, 32224
- Mayo Clinic
-
Jacksonville, Florida, Stany Zjednoczone, 32207
- Baptist Health - Jacksonville
-
Orlando, Florida, Stany Zjednoczone, 32804
- AdventHealth
-
Orlando, Florida, Stany Zjednoczone, 32806
- Orlando Health UF Health Cancer Center
-
Tampa, Florida, Stany Zjednoczone, 33612
- H. Lee Moffitt Cancer Center and Research Institute, Inc
-
-
Georgia
-
Atlanta, Georgia, Stany Zjednoczone, 30342
- Northside Hospital, Inc.
-
Atlanta, Georgia, Stany Zjednoczone, 30309
- Piedmont Healthcare Brain Tumor Center
-
Atlanta, Georgia, Stany Zjednoczone, 30322
- The Emory Clinic - Emory Healthcare - Winship Cancer Institute
-
-
Illinois
-
Chicago, Illinois, Stany Zjednoczone, 60612
- Rush University Medical Center
-
Chicago, Illinois, Stany Zjednoczone, 60617
- University of Chicago
-
-
Indiana
-
Fort Wayne, Indiana, Stany Zjednoczone, 46845
- Parkview Cancer Institute - Fort Wayne Radiation Oncology Associates
-
-
Kansas
-
Topeka, Kansas, Stany Zjednoczone, 66606
- The University of Kansas Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, Stany Zjednoczone, 40241
- Norton Cancer Institute
-
Louisville, Kentucky, Stany Zjednoczone, 40202
- University of Louisville - James Graham Brown Cancer Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Stany Zjednoczone, 70810
- Mary Bird Cancer Center Neuromedical Center
-
New Orleans, Louisiana, Stany Zjednoczone, 70072
- LSU Health Sciences Center, New Orleans
-
New Orleans, Louisiana, Stany Zjednoczone, 70121-2429
- Ochsner Health System
-
-
Maine
-
South Portland, Maine, Stany Zjednoczone, 04106
- Maine Medical Partners Neurology - Neurosurgery & Spine Associates
-
-
Maryland
-
Baltimore, Maryland, Stany Zjednoczone, 21287
- John Hopkins School of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Stany Zjednoczone, 02111
- Tufts Medical Center
-
Worcester, Massachusetts, Stany Zjednoczone, 01655
- University of Massachusetts Chan Medical School
-
-
Michigan
-
Ann Arbor, Michigan, Stany Zjednoczone, 48109
- University of Michigan Comprehensive Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55407
- Abbott Northwestern Hospital - Givens Brain Tumor Center
-
-
Mississippi
-
Jackson, Mississippi, Stany Zjednoczone, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Columbia, Missouri, Stany Zjednoczone, 65212
- University of Missouri - Ellis Fischel Cancer Center
-
Kansas City, Missouri, Stany Zjednoczone, 64132
- Health Midwest Ventures Group, Inc - Sarah Cannon HCA Midwest Brain and Spine
-
St Louis, Missouri, Stany Zjednoczone, 63110
- Washington University School of Medicine
-
-
New Hampshire
-
Lebanon, New Hampshire, Stany Zjednoczone, 03756
- Dartmouth-Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, Stany Zjednoczone, 08820
- JFK Neuroscience Institute, HMH JFK University Medical Center
-
Hackensack, New Jersey, Stany Zjednoczone, 07601
- Hackensack University Medical Center - John Theurer Cancer Center
-
Neptune City, New Jersey, Stany Zjednoczone, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Lake Success, New York, Stany Zjednoczone, 11042
- Northwell Health System Brain Tumor Center
-
New York, New York, Stany Zjednoczone, 10029
- Mount Sinai - Icahn School of Medicine
-
New York, New York, Stany Zjednoczone, 10016
- NYU Langone - Laura & Issac Perimutter Cancer Center
-
New York, New York, Stany Zjednoczone, 10032
- New York Presbyterian - Columbia University
-
Rochester, New York, Stany Zjednoczone, 14642
- University of Rochester Medical Center
-
Syracuse, New York, Stany Zjednoczone, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27599
- University of North Carolina Brain Tumor Program - UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Stany Zjednoczone, 28204
- Novant Health Cancer Institute Radiation Oncology
-
Greenville, North Carolina, Stany Zjednoczone, 27834
- Vidant Medical Center
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27157
- Wake Forest Baptist Comprehensive Cancer Center
-
Winston-Salem, North Carolina, Stany Zjednoczone, 27103
- Forsyth Medical Center-Novant Health
-
-
Ohio
-
Cincinnati, Ohio, Stany Zjednoczone, 45219
- University of Cincinnati Cancer Institute
-
Columbus, Ohio, Stany Zjednoczone, 43210
- The James Cancer Hospital and Solove Research Institute - Arthur G James Cancer Hospital
-
-
Oregon
-
Portland, Oregon, Stany Zjednoczone, 97239
- Oregon Health & Science University (OHSU)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, Stany Zjednoczone, 19104
- Neuroscience Center, Philadelphia - University of Pennsylvania
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Stany Zjednoczone, 15212
- Allegheny Health Network Cancer Institute
-
-
Rhode Island
-
Providence, Rhode Island, Stany Zjednoczone, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Stany Zjednoczone, 29425
- MUSC Radiation Oncology Brain & Spine Tumor Program
-
-
Tennessee
-
Chattanooga, Tennessee, Stany Zjednoczone, 37404
- SCRI - Tennessee Oncology
-
Germantown, Tennessee, Stany Zjednoczone, 38138
- West Cancer Center - Germantown
-
Nashville, Tennessee, Stany Zjednoczone, 37203
- SCRI - Tennessee Oncology
-
-
Texas
-
Austin, Texas, Stany Zjednoczone, 78705
- Texas Oncology Midtown - Austin Brain Tumor Center
-
Dallas, Texas, Stany Zjednoczone, 75246
- Baylor Charles A. Sammons Cancer Center - Baylor University Medical Center
-
Fort Worth, Texas, Stany Zjednoczone, 76104
- John Peter Smith Health Network - JPS Cancer Center
-
Houston, Texas, Stany Zjednoczone, 77030
- Houston Methodist Hospital
-
Houston, Texas, Stany Zjednoczone, 77030
- UT Health Mischer Neuroscience - Memorial Herman - UT Neurosciences
-
Temple, Texas, Stany Zjednoczone, 76508
- Baylor Scott & White Medical Center
-
-
Vermont
-
Burlington, Vermont, Stany Zjednoczone, 05401
- The University of Vermont Medical Center - University of Vermont Cancer Center
-
-
Washington
-
Seattle, Washington, Stany Zjednoczone, 98122
- Swedish Health Services
-
Seattle, Washington, Stany Zjednoczone, 98109
- UW Medical Center - Alvord Brain Tumor Center
-
-
West Virginia
-
Morgantown, West Virginia, Stany Zjednoczone, 26506
- West Virginia University Cancer Institute
-
-
-
-
-
Lausanne, Szwajcaria, CH-1011
- Lausanne University Hospital
-
Zurich, Szwajcaria, 8091
- University Hospital Zurich
-
-
-
-
-
Liverpool, Zjednoczone Królestwo, L7 8YA
- Clatterbridge Cancer Centre
-
London, Zjednoczone Królestwo, SE1 9RT
- Guy's Hospital
-
London, Zjednoczone Królestwo, W6 8RF
- Charing Cross Hospital
-
Nottingham, Zjednoczone Królestwo, NG5 1PB
- Nottingham University Hospitals NHS Trust
-
Preston, Zjednoczone Królestwo, PR29HT
- Royal Preston Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
*Age Limits - 18 years or older outside of the US, 22 years or older within the US.
Inclusion Criteria:
- Histologically confirmed diagnosis of GBM according to WHO 2016 classification criteria.
- Age ≥ 22 years in US and Age ≥ 18 years in Ex-US
- Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
- Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
- Karnofsky performance status ≥ 70
- Life expectancy ≥ least 3 months
- Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed.
- All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted.
- Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable.
- Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
- Women of childbearing potential must have a negative β-HCG pregnancy test documented within 14 days prior to randomization
- Is able to have MRI with contrast of the brain
Exclusion Criteria:
-
Progressive disease (per investigator's assessment)
-
Infratentorial or leptomeningeal disease
-
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
-
Pregnancy or breast-feeding.
-
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator:
- Thrombocytopenia (platelet count < 100 x 103/μL)
- Neutropenia (absolute neutrophil count < 1.5 x 103/μL)
- CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
- Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
- Total bilirubin > 1.5 x upper limit of normal
- Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 µmol/l)
- History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
-
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.
-
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
-
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC.
-
Additional malignancies that are progressing or required active treatment in the last two years.
-
Admitted to an institution by administrative or court order.
-
Known allergies to medical adhesives or hydrogel
-
A skull defect (such as, missing bone with no replacement)
-
Prior radiation treatment to the brain for the treatment of GBM
-
Any serious surgical/post-operative condition that may put the participant at risk according to the investigator.
-
Standard TTFields exclusion criteria include
- Active implanted medical devices
- Bullet fragments
- Skull defects
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Eksperymentalny: Optune® + RT + TMZ for 6 weeks
Optune® + RT + TMZ for 6 weeks, followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
|
Aktywny komparator: RT +TMZ for 6 weeks
RT +TMZ for 6 weeks followed by Optune® + TMZ until the tumor progresses. Optune treatment is maintained until second disease progression. |
Optune® is a commercial, portable, battery-operated device intended for continuous home use, which delivers TTFields at a frequency of 200kHz to the brain by means of insulated transducer arrays. The Optune® device produces electric forces intended to disrupt cancer cell division. In treatment arm I, the patient starts Optune® concurrently with RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. In treatment arm II, the patient starts RT/TMZ for 6 weeks, followed by Optune® + TMZ until second disease progression. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall Survival (OS)
Ramy czasowe: 5 years
|
Survival will be measured from the time of randomization until date patient is alive. |
5 years
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Progression Free Survival (PFS)
Ramy czasowe: 5 years
|
PFS will be measured from the date of randomization to the date of progression based on the 2010 RANO Criteria. |
5 years
|
|
1- and 2-year survival rates
Ramy czasowe: 5 years
|
The analyses will be performed based on estimated proportions of patients who are on study at 12 and 24 months in both arms of the study. |
5 years
|
|
Overall Radiological response (ORR)
Ramy czasowe: 5 years
|
The analyses will be performed based on the 2010 RANO criteria, and comparison between the rates of response. |
5 years
|
|
Next progression-free survival (PFS2)
Ramy czasowe: 5 years
|
PFS2 will be measured from the time of randomization to second tumor progression. |
5 years
|
|
Progression-free survival at 6 (PFS6) and 12 months (PFS12)
Ramy czasowe: 5 years
|
The analyses will be estimated proportions of patients who are progression-free at 6 and 12 months in both arms of the study. |
5 years
|
|
Severity and frequency of adverse events
Ramy czasowe: 5 years
|
The analyses will be performed based on the incidence, severity, frequency of adverse events, and their association with study treatments. |
5 years
|
|
Quality of Life EORTC Questionnaire
Ramy czasowe: 5 years
|
The analyses will be assessed using the EORTC QLQ C-30 questionnaire with BN-20 (brain symptom) supplement. |
5 years
|
|
The NANO scale
Ramy czasowe: 5 years
|
The Neurological assessment in Neuro-Oncology will be assessed using the NANO scale questionnaire and per the 2010 RANO criteria. |
5 years
|
Współpracownicy i badacze
Sponsor
Sponsor
Publikacje i pomocne linki
Publikacje ogólne
- Miller R, Niazi M, Russial O, Poiset S, Shi W. Tumor treating fields with radiation for glioblastoma: a narrative review. Chin Clin Oncol. 2022 Oct;11(5):40. doi: 10.21037/cco-22-90.
- Miller R, Song A, Ali A, Niazi M, Bar-Ad V, Martinez N, Glass J, Alnahhas I, Andrews D, Judy K, Evans J, Farrell C, Werner-Wasik M, Chervoneva I, Ly M, Palmer J, Liu H, Shi W. Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma. Front Oncol. 2022 Apr 29;12:896246. doi: 10.3389/fonc.2022.896246. eCollection 2022.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Zakończenie podstawowe
Ukończenie studiów (Rzeczywisty)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- TRIDENT EF-32
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .